leflunomide has been researched along with Hypertension in 10 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 9.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 9.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 7.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "To determine the frequency of new-onset hypertension in patients with Rheumatoid arthritis taking leflunomide, in comparison with methotrexate in Asian setting." | 5.30 | Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg. ( Ishaq, M; Kumar, A; Muhammad, JS; Razzaque, S; Shohail, F, 2019) |
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 5.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 5.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| " Mycophenolate and leflunomide are teratogenic drugs and should be withdrawn before conception in case of programmed pregnancy or should be rapidly discontinued in case of unexpected pregnancy." | 4.91 | Immunosuppression in pregnant women with systemic lupus erythematosus. ( Moroni, G; Ponticelli, C, 2015) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 3.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| "Patients with treated hypertension should be monitored regularly when conventional NSAIDs or COX-2 inhibitors are administered." | 2.41 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. ( Dijkmans, BA; Nurmohamed, MT; van Halm, VP, 2002) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kramarič, J | 1 |
| Ješe, R | 1 |
| Tomšič, M | 2 |
| Rotar, Ž | 1 |
| Hočevar, A | 1 |
| Ishaq, M | 1 |
| Razzaque, S | 1 |
| Shohail, F | 1 |
| Kumar, A | 1 |
| Muhammad, JS | 1 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 1 |
| George, M | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 1 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 1 |
| Ponticelli, C | 1 |
| Moroni, G | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Gugenberger, C | 1 |
| Donner, P | 1 |
| Naami, A | 1 |
| Berges, W | 1 |
| Kellner, H | 1 |
| Bornholdt, K | 1 |
| Hein, G | 1 |
| Nurmohamed, MT | 1 |
| van Halm, VP | 1 |
| Dijkmans, BA | 1 |
| Rozman, B | 1 |
| Praprotnik, S | 1 |
| Logar, D | 1 |
| Hojnik, M | 1 |
| Kos-Golja, M | 1 |
| Accetto, R | 1 |
| Dolenc, P | 1 |
| Kiely, PD | 1 |
| Johnson, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
3 reviews available for leflunomide and Hypertension
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Immunosuppression in pregnant women with systemic lupus erythematosus.
Topics: Contraindications; Cyclosporine; Female; Glucocorticoids; Humans; Hypertension; Immunosuppression Th | 2015 |
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular | 2002 |
3 trials available for leflunomide and Hypertension
| Article | Year |
|---|---|
Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg.
Topics: Adult; Arthritis, Rheumatoid; Asian People; Case-Control Studies; Female; Humans; Hypertension; Immu | 2019 |
Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Di | 2010 |
Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
Topics: Adult; Aged; Anaphylaxis; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoa | 2002 |
4 other studies available for leflunomide and Hypertension
| Article | Year |
|---|---|
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |
[Persistent diarrhea and loss of weight during therapy with leflunomide].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Colitis, Lymphocytic; Diabetes Mellitus, Type 1; Diarrh | 2008 |
Leflunomide and hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Hypertension; Isoxazoles; Le | 2002 |